mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28- Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection. [electronic resource]
Producer: 20201007Description: 1058-1069 p. digitalISSN:- 1534-6080
- Abatacept -- pharmacology
- Biopsy
- CD28 Antigens -- immunology
- CD8-Positive T-Lymphocytes -- immunology
- Female
- Graft Rejection -- drug therapy
- Graft Survival
- Humans
- Immunologic Memory -- drug effects
- Immunosuppression Therapy -- methods
- Immunosuppressive Agents -- pharmacology
- Kidney -- pathology
- Kidney Transplantation
- Male
- Middle Aged
- Sirolimus -- pharmacology
- T-Lymphocytes, Regulatory -- drug effects
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
- Tacrolimus -- pharmacology
- Transplantation, Homologous
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.